Tanzania
Research Article
Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures
Author(s): Nagi Kumar, Theresa Crocker, Tiffany Smith, Julio Pow-Sang, Philippe E. Spiess, Shanjayla Connors, Ganna Chornukur, Shohreh Iravani Dickinson, Wenlong Bai, Christopher R. Williams, Raoul Salup and Wui FuNagi Kumar, Theresa Crocker, Tiffany Smith, Julio Pow-Sang, Philippe E. Spiess, Shanjayla Connors, Ganna Chornukur, Shohreh Iravani Dickinson, Wenlong Bai, Christopher R. Williams, Raoul Salup and Wui Fu
Inspite of the large number of promising nutrient-derived agents demonstrating promise as potential chemopreventive agents, most have failed to prove effectiveness in clinical trials. Critical requirements for moving nutrient-derived agents to recommendation for clinical use include adopting a systematic, molecular-mechanism based approach and utilizing the same ethical and rigorous methods such as are used to evaluate other pharmacological agents. Preliminary data on a mechanistic rationale for chemoprevention activity as observed from epidemiological, in vitro and preclinical studies, phase I data of safety in high-risk cohorts are required to inform design of phase II clinical trials. Additionally, a valid panel of biomarkers representing the hypothesized carcinogenesis pathway for measuring efficacy mus.. Read More»
DOI:
10.4172/1948-5956.S3-007
Cancer Science & Therapy received 3968 citations as per Google Scholar report